ReNAgade

Cambridge, United States Founded: 2021 • Age: 5 yrs Acquired By Orna
RNA-based medicines are developed for treating multiple diseases.
Request Access

About ReNAgade

ReNAgade is a company based in Cambridge (United States) founded in 2021 was acquired by Orna in May 2024.. ReNAgade has raised $300 million across 1 funding round from investors including Orna, Turmeric Acquisition Corp and F2 Ventures. The company has 136 employees as of December 31, 2022. ReNAgade operates in a competitive market with competitors including Stoke Therapeutics, Vico, MiNA Therapeutics, Ribometrix and Creyon Bio, among others.

  • Headquarter Cambridge, United States
  • Employees 136 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Renagade Therapeutics Management, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $300 M (USD)

    in 1 rounds

  • Latest Funding Round
    $300 M (USD), Series A

    May 23, 2023

  • Investors
    Orna

    & 2 more

  • Employee Count
    136

    as on Dec 31, 2022

  • Acquired by
    Orna

    (May 23, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of ReNAgade
Headcount 50-200
Employee Profiles 4
Employee Profiles
People
Joel Yeshman
Senior Director Finance
People
Stevelyn Desire aPHR®
Senior Associate People Experience
People
Meredith Jones
Associate Director, Legal Operations

Unlock access to complete

Funding Insights of ReNAgade

ReNAgade has successfully raised a total of $300M through 1 strategic funding round. The most recent funding activity was a Series A round of $300 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $300.0M
  • First Round

    (23 May 2023)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2023 Amount Series A - ReNAgade Valuation MPM Capital , F2 Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ReNAgade

ReNAgade has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Orna, Turmeric Acquisition Corp and F2 Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Invests in biotech firms developing life-saving drugs and technologies.
Founded Year Domain Location
Technologies for producing circular RNA therapeutics are developed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ReNAgade

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ReNAgade

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Renagade Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ReNAgade

ReNAgade operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Stoke Therapeutics, Vico, MiNA Therapeutics, Ribometrix and Creyon Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing
domain founded_year HQ Location
RNA modulating therapies for genetic neurological diseases are developed.
domain founded_year HQ Location
Small activating RNA therapeutics are developed to restore gene function.
domain founded_year HQ Location
RNA-targeted drug discovery platform using three-dimensional structural analysis is provided.
domain founded_year HQ Location
Oligonucleotide-based drug development platform is provided using AI models.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Renagade

Frequently Asked Questions about ReNAgade

When was ReNAgade founded?

ReNAgade was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is ReNAgade located?

ReNAgade is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Who is the current CEO of ReNAgade?

Amit Munshi is the current CEO of ReNAgade.

Is ReNAgade a funded company?

ReNAgade is a funded company, having raised a total of $300M across 1 funding round to date. The company's 1st funding round was a Series A of $300M, raised on May 23, 2023.

How many employees does ReNAgade have?

As of Dec 31, 2022, the latest employee count at ReNAgade is 136.

What does ReNAgade do?

ReNAgade was founded in 2021 and is based in Cambridge, United States. RNA-based medicines are developed by the company to address various diseases. Novel RNA delivery platforms are combined to enable coding, editing, and gene insertion functionalities. Operations focus on advancing therapeutic innovations within the biotechnology sector, with emphasis on precise genetic modifications for medical applications.

Who are the top competitors of ReNAgade?

ReNAgade's top competitors include MiNA Therapeutics, Vico and Stoke Therapeutics.

Who are ReNAgade's investors?

ReNAgade has 3 investors. Key investors include Orna, Turmeric Acquisition Corp, and F2 Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available